These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 15565383

  • 1. [Interferon therapy of multiple sclerosis. Synopsis of various dosage forms].
    Jarius S, Hohlfeld R.
    Nervenarzt; 2004 Dec; 75(12):1226-30. PubMed ID: 15565383
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor).
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Dec; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract] [Full Text] [Related]

  • 6. [Interferon beta treatment of disseminated sclerosis in Denmark--current status].
    Sørensen PS.
    Ugeskr Laeger; 2000 Nov 06; 162(45):6091-3. PubMed ID: 11107953
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β.
    Hegen H, Auer M, Deisenhammer F.
    Expert Opin Drug Metab Toxicol; 2015 Nov 06; 11(12):1803-19. PubMed ID: 26419922
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Crohn's disease during the course of multiple sclerosis: role of interferon-beta therapy].
    Samson M, Audia S, Duchêne C, Perinet I, Bielefeld P, Besancenot JF.
    Rev Med Interne; 2009 Sep 06; 30(9):816-9. PubMed ID: 19201069
    [Abstract] [Full Text] [Related]

  • 11. [Practical advice for a safe, effective and well tolerated therapy of multiple sclerosis].
    Buttmann M, Rieckmann P.
    MMW Fortschr Med; 2006 May 15; Spec no. 2():49-50, 52-3. PubMed ID: 20104715
    [Abstract] [Full Text] [Related]

  • 12. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov 01; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis.
    Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist LW, von Koch L.
    Acta Neurol Scand; 2007 Aug 01; 116(2):96-9. PubMed ID: 17661794
    [Abstract] [Full Text] [Related]

  • 16. Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient.
    Amschler K, Meyersburg D, Kitze B, Schön MP, Mössner R.
    Eur J Dermatol; 2016 Apr 01; 26(2):211-2. PubMed ID: 27125193
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Retinopathy in a multiple sclerosis patient undergoing interferon-therapy.
    Saito H, Suzuki M, Asakawa T, Kato S.
    Mult Scler; 2007 Aug 01; 13(7):939-40. PubMed ID: 17468441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.